Pharmacy

Bristol-Myers Squibb   (BMS) has recently signed a immunity-from-suit agreement with Matrix Laboratories Ltd to expand access to Reyataz® (atazanavir sulfate). This agreement will enable the generic company to manufacture and sell atazanavir as well as stavudine and didanosine in India and sub-Saharan Africa. Atazanavir is an important component of HIV combination therapy and this agreement will facilitate broader availability of the medicine in the

developing worlds. This is the fifteenth agreement that BMS has signed for its HIV medicines, and the fourth for atazanavir. A key component of the agreement is the inclusion of pediatric formulations of the medicines to support the treatment needs of children with HIV.  WHO prequalification enables procurement organizations to purchase medicines using funding from United Nations agencies and the global fund to fight AIDS, tuberculosis and malaria?